Do I need a prescription for Ciclesonide 80micrograms/dose inhaler CFC free?

Ciclesonide 80micrograms/dose inhaler CFC free is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ciclesonide 80micrograms/dose inhaler CFC free?

Ciclesonide 80micrograms/dose inhaler CFC free is the generic name. It is available under brand names including: Alvesco 80 inhaler, Alvesco 80 inhaler, Alvesco 80 inhaler, Alvesco 80 inhaler, Ciclesonide 80micrograms/dose inhaler CFC free and 2 more. (Source: NHS dm+d — Actual Medicinal Products)

Ciclesonide 80micrograms/dose inhaler CFC free

Prescription only

Requires a prescription from a doctor or prescriber

Inhaler

Inhalation

Asthma treatment

Asthma treatment (at risk)

COVID-19 COPD drug

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases.

Active ingredients:

Ciclesonide

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC R03BA08

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Asthma treatment

Asthma treatment (at risk)

COVID-19 COPD drug

Check interactions for Ciclesonide

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ciclesonide

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ciclesonide

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ciclesonide

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

7 branded products available

7 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ciclesonide on the MHRA register

Alvesco 80 inhaler

Covis Pharma GmbH

Alvesco 80 inhaler

Lexon (UK) Ltd

Ciclesonide 80micrograms/dose inhaler CFC free

Advanz Pharma

Ciclesonide 80micrograms/dose inhaler CFC free

Alliance Healthcare (Distribution) Ltd

Ciclesonide 80micrograms/dose inhaler CFC free

A A H Pharmaceuticals Ltd

Alvesco 80 inhaler

Mawdsley-Brooks & Company Ltd

Discontinued

Alvesco 80 inhaler

Waymade Healthcare Plc

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Price & daily dose

£32.83indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

160 microgram

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

Other

2ml

Same therapeutic group

Budesonide 1mg/2ml nebuliser suspension unit dose ampoules

Other

1mg/2ml

Same therapeutic group

Budesonide 200micrograms/dose inhaler CFC free

Inhaler

Same therapeutic group

Budesonide 100micrograms/dose inhaler CFC free

Inhaler

Same therapeutic group

Beclometasone 200micrograms/dose inhaler CFC free

Inhaler

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

9004511000001107

dm+d ID

9004511000001107

VTM (Virtual Therapeutic Moiety)

775240002

VMP (Virtual Medicinal Product)

9004511000001107

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

R03BA08

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 16 · Randomised trials: 14 · 2006–2026

Sort

Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?

Thera Gram Ottesen, Alma Holm Rovsing, Charlotte Suppli Ulrik

Respiratory Medicine, 2025

Systematic review

Cited by 12

Asthma
Pregnenediones
Adrenal Cortex Hormones

Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised Trial.

Wark P, Marschner IC, Hutchings O, et al.

2026

Systematic review

Cited by 2

Pregnenediones
COVID-19
COVID-19 Drug Treatment

Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.

B. Clemency, R. Varughese, Y. Gonzalez-Rojas, et al.

JAMA internal medicine, 2021

Randomised trial

Cited by 92

COVID-19 Drug Treatment
Pregnenediones
Glucocorticoids

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

N. Ezer, S. Belga, N. Daneman, et al.

The BMJ, 2021

Randomised trial

Cited by 81

Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis.

Hsu CK, Chao CM, Lai CC

2022

Meta-analysis

Cited by 3

Asthma
Pregnenediones
Anti-Asthmatic Agents

Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).

Brodin D, Tornhammar P, Ueda P, et al.

2023

Randomised trial

Cited by 8

Pregnenediones
COVID-19
Oxygen

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

S. Matsuyama, Miyuki Kawase, Naganori Nao, et al.

Journal of Virology, 2020

Cited by 177

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

S. Matsuyama, Miyuki Kawase, Naganori Nao, et al.

bioRxiv, 2020

Cited by 175

Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.

Manabu Suzuki, Akihiro Matsunaga, T. Miyoshi-Akiyama, et al.

Drug discoveries & therapeutics, 2023

Randomised trial

Cited by 1

Asthma
Pregnenediones
COVID-19

Ciclesonide inhaler for post-acute COVID-19 syndrome: promisingclinical evidence

J. Shareef, T. Sabin, S. Sridhar, et al.

Pharmacy Practice, 2024

Randomised trial

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

Not available

Mechanism

Glucocorticoids such as ciclesonide can inhibit leukocyte infiltration at the si…

Food interactions

None known

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism.…

Protein binding

99%

The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged ≥ 99% each, with ≤ 1% of unbound drug detected in the systemic circulation.…

Metabolism

Des-ciclesonide undergoes metabolism in the liver to additional metabolites mainly by the cytochrome P450 (CYP) 3A4 isozyme and to a lesser extent by CYP 2D6.…

Clearance

152 L/h

* 152 L/hr [Following IV administration of 800 mcg of ciclesonide]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Properties:

solid

Avg. mass: 540.70 Da

DrugBank indication

For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Also known as(52)

Ciclesonida

Ciclesonide

GRL

Nuclear receptor subfamily 3 group C member 1

CBG

Serpin A6

Transcortin

Molecular properties(19)

Drug interactions(1256)

Known interactions with other medicines. Always consult a healthcare professional.

Denosumab

Moderate

DB06643

The risk or severity of adverse effects can be increased when Denosumab is combined with Ciclesonide.

Check this interaction

Peginterferon alfa-2a

Moderate

DB00008

The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ciclesonide.

Check this interaction

Interferon alfa-n1

Moderate

DB00011

The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ciclesonide.

Check this interaction

Interferon alfa-n3

Moderate

DB00018

The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ciclesonide.

Check this interaction

Peginterferon alfa-2b

Moderate

DB00022

The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ciclesonide.

Check this interaction

Interferon gamma-1b

Moderate

DB00033

The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ciclesonide.

Check this interaction

Interferon alfa-2a

Moderate

DB00034

The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ciclesonide.

Check this interaction

Gemtuzumab ozogamicin

Moderate

DB00056

The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.

Check this interaction

Pegaspargase

Moderate

DB00059

The serum concentration of Ciclesonide can be increased when it is combined with Pegaspargase.

Check this interaction

Interferon beta-1b

Moderate

DB00068

The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ciclesonide.

Check this interaction

Interferon alfacon-1

Moderate

DB00069

The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ciclesonide.

Check this interaction

Rituximab

Moderate

DB00073

The risk or severity of adverse effects can be increased when Rituximab is combined with Ciclesonide.

Check this interaction

Basiliximab

Moderate

DB00074

The risk or severity of adverse effects can be increased when Basiliximab is combined with Ciclesonide.

Check this interaction

Muromonab

Moderate

DB00075

The risk or severity of adverse effects can be increased when Muromonab is combined with Ciclesonide.

Check this interaction

Ibritumomab tiuxetan

Moderate

DB00078

The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.

Check this interaction

Tositumomab

Moderate

DB00081

The risk or severity of adverse effects can be increased when Tositumomab is combined with Ciclesonide.

Check this interaction

Alemtuzumab

Moderate

DB00087

The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ciclesonide.

Check this interaction

Alefacept

Moderate

DB00092

The risk or severity of adverse effects can be increased when Alefacept is combined with Ciclesonide.

Check this interaction

Efalizumab

Moderate

DB00095

The risk or severity of adverse effects can be increased when Efalizumab is combined with Ciclesonide.

Check this interaction

Antithymocyte immunoglobulin (rabbit)

Moderate

DB00098

The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ciclesonide.

Check this interaction

Interferon alfa-2b

Moderate

DB00105

The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ciclesonide.

Check this interaction

Daclizumab

Moderate

DB00111

The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.

Check this interaction

Phenylalanine

Moderate

DB00120

The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ciclesonide.

Check this interaction

Bortezomib

Moderate

DB00188

The risk or severity of adverse effects can be increased when Bortezomib is combined with Ciclesonide.

Check this interaction

Cladribine

Moderate

DB00242

Ciclesonide may increase the immunosuppressive activities of Cladribine.

Check this interaction

Carmustine

Moderate

DB00262

The risk or severity of adverse effects can be increased when Carmustine is combined with Ciclesonide.

Check this interaction

Amsacrine

Moderate

DB00276

The risk or severity of adverse effects can be increased when Amsacrine is combined with Ciclesonide.

Check this interaction

Bleomycin

Moderate

DB00290

The risk or severity of adverse effects can be increased when Bleomycin is combined with Ciclesonide.

Check this interaction

Chlorambucil

Moderate

DB00291

The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ciclesonide.

Check this interaction

Raltitrexed

Moderate

DB00293

The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ciclesonide.

Check this interaction

Mitomycin

Moderate

DB00305

The risk or severity of adverse effects can be increased when Mitomycin is combined with Ciclesonide.

Check this interaction

Bexarotene

Moderate

DB00307

The risk or severity of adverse effects can be increased when Bexarotene is combined with Ciclesonide.

Check this interaction

Vindesine

Moderate

DB00309

The risk or severity of adverse effects can be increased when Vindesine is combined with Ciclesonide.

Check this interaction

Floxuridine

Moderate

DB00322

The risk or severity of adverse effects can be increased when Floxuridine is combined with Ciclesonide.

Check this interaction

Tioguanine

Moderate

DB00352

The risk or severity of adverse effects can be increased when Tioguanine is combined with Ciclesonide.

Check this interaction

Vinorelbine

Moderate

DB00361

The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ciclesonide.

Check this interaction

Dexrazoxane

Moderate

DB00380

The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ciclesonide.

Check this interaction

Sorafenib

Moderate

DB00398

The risk or severity of adverse effects can be increased when Sorafenib is combined with Ciclesonide.

Check this interaction

Streptozocin

Moderate

DB00428

The risk or severity of adverse effects can be increased when Streptozocin is combined with Ciclesonide.

Check this interaction

Trifluridine

Moderate

DB00432

The risk or severity of adverse effects can be increased when Trifluridine is combined with Ciclesonide.

Check this interaction

Gemcitabine

Moderate

DB00441

The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ciclesonide.

Check this interaction

Teniposide

Moderate

DB00444

The risk or severity of adverse effects can be increased when Teniposide is combined with Ciclesonide.

Check this interaction

Epirubicin

Moderate

DB00445

The risk or severity of adverse effects can be increased when Epirubicin is combined with Ciclesonide.

Check this interaction

Chloramphenicol

Moderate

DB00446

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ciclesonide.

Check this interaction

Lenalidomide

Moderate

DB00480

The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ciclesonide.

Check this interaction

Altretamine

Moderate

DB00488

The risk or severity of adverse effects can be increased when Altretamine is combined with Ciclesonide.

Check this interaction

Zidovudine

Moderate

DB00495

The risk or severity of adverse effects can be increased when Zidovudine is combined with Ciclesonide.

Check this interaction

Oxaliplatin

Moderate

DB00526

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ciclesonide.

Check this interaction

Cyclophosphamide

Moderate

DB00531

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ciclesonide.

Check this interaction

Vincristine

Moderate

DB00541

The risk or severity of adverse effects can be increased when Vincristine is combined with Ciclesonide.

Check this interaction

Showing 50 of 1256 interactions

How it works

Mechanism of action

Glucocorticoids such as ciclesonide can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Ciclesonide reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Ciclesonide is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.

Pharmacodynamics

Ciclesonide is a pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120 times higher than the parent compound. The precise mechanism through which ciclesonide affects allergic rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic inflammation.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism. The intranasal administration of ciclesonide at recommended doses results in negligible serum concentrations of ciclesonide.

Protein binding

The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged ≥ 99% each, with ≤ 1% of unbound drug detected in the systemic circulation.

Metabolism

Des-ciclesonide undergoes metabolism in the liver to additional metabolites mainly by the cytochrome P450 (CYP) 3A4 isozyme and to a lesser extent by CYP 2D6.

Clearance

* 152 L/hr [Following IV administration of 800 mcg of ciclesonide]

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Glucocorticoid receptor

BE0000794

NR3C1

agonist

Specific functioncore promoter sequence-specific DNA binding

Cellular location

Cytoplasm

General function & pharmacology

Receptor for glucocorticoids (GC) .
PMID:27120390 PMID:37478846
Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors .
PMID:28139699
Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling .
PMID:9590696
Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay .
PMID:25775514
Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)

Corticosteroid-binding globulin

BE0000209

SERPINA6

binder

Specific functionmolecular carrier activity

Cellular location

Secreted

General function & pharmacology

Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CES1Liver carboxylesterase 1

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP2D6Cytochrome P450 2D6

substrate

Carriers(1)

Proteins that carry this drug through the body

Corticosteroid-binding globulin

BE0000209

SERPINA6

binder

Specific functionmolecular carrier activity

Cellular location

Secreted

General function & pharmacology

Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species

Scientific references(1)

Mutch E., Nave R., McCracken N., Zech K., Williams F.M.

The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.

Biochemical Pharmacology

200773(10):1657-1664. doi: 10.1016/j.bcp.2007.01.031

PMID: 17331475 DOI: 10.1016/j.bcp.2007.01.031

ATC classification(2 codes)

ATC R03BA08

ATC R01AD13

Affected organisms(1)

Humans and other mammals

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ciclesonide

DB01410

CAS number

126544-47-6

UNII (FDA)

S59502J185

InChI Key (molecular fingerprint)

LUKZNWIVRBCLON-GXOBDPJESA-N

Additional database identifiers

Drugs Product Database (DPD)

19961

ChEBI

31397

PubChem Compound

6918155

PubChem Substance

46508553

KEGG Drug

D01703

ChemSpider

5293368

BindingDB

50247997

PharmGKB

PA164781399

Therapeutic Targets Database

DAP000423

Wikipedia

Ciclesonide

ChEMBL

CHEMBL2040682

ZINC

ZINC000003915154

RxCUI

274964

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7978

GenAtlas

NR3C1

GeneCards

NR3C1

GenBank Gene Database

X03225

GenBank Protein Database

31680

IUPHAR

625

Guide to Pharmacology

625

UniProtKB

P04150

UniProt Accession

GCR_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1540

GenAtlas

SERPINA6

GeneCards

SERPINA6

GenBank Gene Database

J02943

GenBank Protein Database

179971

UniProtKB

P08185

UniProt Accession

CBG_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1863

GenAtlas

CES1

GeneCards

CES1

GenBank Gene Database

M73499

Guide to Pharmacology

2592

UniProtKB

P23141

UniProt Accession

EST1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1540

GenAtlas

SERPINA6

GeneCards

SERPINA6

GenBank Gene Database

J02943

GenBank Protein Database

179971

UniProtKB

P08185

UniProt Accession

CBG_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Ciclesonide 80micrograms/dose inhaler CFC free

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Protein binding

Metabolism

Clearance

Clinical essentials

Pharmacology

Deep science
6

Chemical identifiers

Ciclesonide

Additional database identifiers

DrugBank citations

Ciclesonide 80micrograms/dose inhaler CFC free

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Protein binding

Metabolism

Clearance

Clinical essentials

Pharmacology

Deep science6

Chemical identifiers

Ciclesonide

Additional database identifiers

DrugBank citations

Deep science
6